We are live on ! Find out more
PI

Pharmstandard International Portfolio holdings

AUM $29M
1-Year Est. Return 3.25%
This Fund
S&P 500
This Quarter Est. Return
-1.24%
1 Year Est. Return
+3.25%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$29M
AUM Growth
+$4.11M
Cap. Flow
+$6.47M
Cap. Flow %
22.27%
Top 10 Hldgs %
100%
Holding
7
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
NTGN
Neon Therapeutics, Inc. Common Stock
NTGN
+$6.52M

Top Sells

Rank Stock Value
1
ALNA
Allena Pharmaceuticals
ALNA
+$56.1K

Sector Composition

Rank Sector Weight
1 Healthcare 99.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNA
1
DELISTED
Allena Pharmaceuticals
ALNA
$9.38M 32.28%
873,031
-5,100
-0.6% -$56.1K
PTGX icon
2
Protagonist Therapeutics
PTGX
$8.71B
$7.72M 26.59%
750,632
– –
NTGN
3
DELISTED
Neon Therapeutics, Inc. Common Stock
NTGN
$5.03M 17.31%
+588,611
New +$6.52M
JNCE
4
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$3.67M 12.65%
565,063
– –
TARA icon
5
Protara Therapeutics
TARA
$229M
$3.13M 10.79%
40,195
– –
ARGS
6
DELISTED
Argos Therapeutics, Inc.
ARGS
$83K 0.29%
826,153
– –
ARGS
7
CALL
DELISTED
Argos Therapeutics, Inc.
ARGS
$26K 0.09%
256,030
– –

Similar funds

IP
Ironsides Partners Boston, Massachusetts $27.7M AUM 1.11% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
MC
Marcus Capital Northbrook, Illinois $34.3M AUM 30.44% 1-Year Est. Return
RIA
Rocaton Investment Advisors Norwalk, Connecticut $36.6M AUM 10.31% 1-Year Est. Return
FC
Flaherty & Crumrine Pasadena, California $19.8M AUM 3.53% 1-Year Est. Return
WFC
West Face Capital Toronto, Ontario, Canada $16.6M AUM 18.79% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
DCM
Dearborn Capital Management Chicago, Illinois $41.6M AUM 2.79% 1-Year Est. Return

Pharmstandard International's Q3 2018 Portfolio in Review

As of Q3 2018, Pharmstandard International held 7 positions worth $29M, up 16% from $24.9M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Pharmstandard International deployed $6.47M of net new capital in Q3 2018, opening 1 new position. Its largest new stake was Neon Therapeutics, Inc. Common Stock: 588,611 shares worth $5.03M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Allena Pharmaceuticals, an estimated $56.1K trimmed.

  • Pharmstandard International's largest Q3 2018 buy was Neon Therapeutics, Inc. Common Stock: 588,611 shares worth $5.03M.
  • Pharmstandard International's biggest Q3 2018 reduction was Allena Pharmaceuticals, cutting an estimated $56.1K.
  • Pharmstandard International's ten largest holdings make up 100% of its $29M portfolio in Q3 2018.
  • Pharmstandard International opened 1 new position and closed 0 in Q3 2018.
  • Pharmstandard International's portfolio value rose 16% quarter-over-quarter to $29M.

Based on Pharmstandard International's 13F filing for Q3 2018, filed 15 Nov 2018.